Rakesh serves on Prescient’s Board as a Non-Executive Director. After earning a degree in Veterinary Medicine, he completed his MS in Immunology and his PhD in Immunology and Oncology at Imperial College School of Medicine in London. He was then recruited by the oncology biotechnology firm Antisoma, which specializes in the development of antibody-based therapeutics for oncology. After working in oncology drug development for more than a decade, Rakesh joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.
Featured
The Living Launch Plan: Keeping Pharma Launch Strategy Aligned
Discover how a living launch plan helps pharmaceutical teams adapt to evolving evidence, competitive dynamics, and changing market conditions.
News and insights
Featured
The New Drivers of Pharma Launch Uptake
Learn why precision in launch strategy is becoming essential for improving pharmaceutical launch uptake and commercial performance.
One-Size-Fits-All Launches Are Over
Read the article to discover why modern pharma launches require a precision approach, helping teams prioritize Must-Win Moments, reduce risk, and improve launch success.
ONWARD: Driving Equitable Access and System Readiness in Cancer Care
This Dolon Institute paper highlights six interconnected barriers affecting timely access to oncology innovation, drawing on examples from healthcare systems around the world.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
